Regencell Bioscience Holdings Limited RGC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -268.89% | -268.89% | -186.90% | -186.90% | -- |
| Total Depreciation and Amortization | 6.69% | 6.69% | -21.24% | -21.24% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,426.67% | 1,426.67% | 2,640.41% | 2,640.41% | -- |
| Change in Net Operating Assets | 2,021.28% | 2,021.28% | -- | -- | -- |
| Cash from Operations | -262.04% | -262.04% | -52.11% | -52.11% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -100.00% | 879.66% | 879.66% | -- |
| Cash from Investing | -100.00% | -100.00% | 879.66% | 879.66% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 96.18% | 96.18% | -59.62% | -59.62% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,304.27% | 1,304.27% | 95.52% | 95.52% | -- |